Analysts Expect Omega Therapeutics Inc (NASDAQ:OMGA) to Post -$0.49 EPS

Equities analysts expect that Omega Therapeutics Inc (NASDAQ:OMGA) will report ($0.49) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have issued estimates for Omega Therapeutics’ earnings. The lowest EPS estimate is ($0.55) and the highest is ($0.46). The firm is expected to issue its next earnings report on Friday, December 10th.

According to Zacks, analysts expect that Omega Therapeutics will report full-year earnings of ($2.60) per share for the current year, with EPS estimates ranging from ($3.07) to ($1.77). For the next year, analysts anticipate that the business will post earnings of ($3.53) per share, with EPS estimates ranging from ($3.92) to ($3.31). Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that cover Omega Therapeutics.

Omega Therapeutics (NASDAQ:OMGA) last released its quarterly earnings results on Friday, September 10th. The company reported ($3.36) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by ($2.94).

A number of equities analysts recently commented on OMGA shares. The Goldman Sachs Group started coverage on Omega Therapeutics in a report on Tuesday, August 24th. They set a “neutral” rating and a $22.00 price target for the company. Piper Sandler started coverage on Omega Therapeutics in a report on Tuesday, August 24th. They set an “overweight” rating and a $30.00 price target for the company. Jefferies Financial Group started coverage on Omega Therapeutics in a report on Tuesday, August 24th. They set a “buy” rating and a $30.00 price target for the company. Finally, Wedbush started coverage on Omega Therapeutics in a report on Tuesday, August 24th. They set an “outperform” rating and a $36.00 price target for the company.

Shares of NASDAQ:OMGA traded up $0.28 during midday trading on Wednesday, reaching $18.49. The company had a trading volume of 327 shares, compared to its average volume of 130,174. Omega Therapeutics has a 1-year low of $15.50 and a 1-year high of $24.29.

About Omega Therapeutics

Omega Therapeutics Inc is a development-stage biotechnology company. Its OMEGA Epigenomic Programming(TM) platform harness the power of epigenetics to develop a new class of DNA-sequence-targeting, mRNA-encoded programmable epigenetic medicines. Omega Therapeutics Inc is based in CAMBRIDGE, Mass.

Featured Article: Stock Symbols and CUSIP Explained

Get a free copy of the Zacks research report on Omega Therapeutics (OMGA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Omega Therapeutics (NASDAQ:OMGA)

Receive News & Ratings for Omega Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omega Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.